Diana Mckenzie - 01 May 2023 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
Director
Signature
/s/ Christiana Stevenson, Attorney-in-Fact
Issuer symbol
VRTX
Transactions as of
01 May 2023
Net transactions value
$0
Form type
4
Filing time
03 May 2023, 17:01:58 UTC
Previous filing
18 Apr 2023
Next filing
16 Jun 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Disposed to Issuer -1,449 -50% 1,435 01 May 2023 Direct F1
transaction VRTX Common Stock Award $0 +1,168 +81% $0.000000 2,603 01 May 2023 Direct F2
holding VRTX Common Stock 207 01 May 2023 Held in Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VRTX Deferred Stock Units Award +1,449 +46% 4,567 01 May 2023 Common Stock 1,449 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Upon the vesting of restricted stock units granted to Ms. McKenzie on May 1, 2022, Ms. McKenzie deferred the receipt of 1,449 shares of common stock and received instead 1,449 deferred stock units pursuant to our deferred compensation plan. As a result, Ms. McKenzie is reporting the disposition of 1,449 shares of common stock in exchange for an equal number of deferred stock units.
F2 Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date.
F3 Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death.